Linked Life Data

12747282

Source:http://linkedlifedata.com/resource/pubmed/id/12747282

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12747282rdf:typepubmed:Citationlld:pubmed
pubmed-article:12747282lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0021760lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0262950lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0878675lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C1749467lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0012544lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0243127lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0206015lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C2267018lld:lifeskim
pubmed-article:12747282lifeskim:mentionsumls-concept:C0443331lld:lifeskim
pubmed-article:12747282pubmed:issue2lld:pubmed
pubmed-article:12747282pubmed:dateCreated2003-5-15lld:pubmed
pubmed-article:12747282pubmed:abstractTextErdheim-Chester disease (ECD) is a rare non-Langherans form of histiocytosis characterized radiologically by symmetrical sclerosis of the metaphysis and the diaphysis of long tubular bones. Macrophages are potent interleukin-6 (IL-6) producers and elevated IL-6 serum levels have been described in pathological conditions characterized by increased bone resorption. In a patient with ECD, during the acute phase of the disease we found high serum levels of IL-6 and IL-6 soluble receptor (sIL-6R) and high levels of bone turnover markers. After 5 years of combination therapy with oral prednisone and intravenous clodronate a significant reduction in the above mentioned biological parameters was seen. We suggest that the systemic disorders present in ECD could be related to the high serum levels of IL-6 and sIL-6R. We also propose the use of bisphosphonates in the clinical management of ECD.lld:pubmed
pubmed-article:12747282pubmed:languageenglld:pubmed
pubmed-article:12747282pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:citationSubsetIMlld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12747282pubmed:statusMEDLINElld:pubmed
pubmed-article:12747282pubmed:issn0392-856Xlld:pubmed
pubmed-article:12747282pubmed:authorpubmed-author:SommoFFlld:pubmed
pubmed-article:12747282pubmed:authorpubmed-author:PostiglioneLLlld:pubmed
pubmed-article:12747282pubmed:authorpubmed-author:NunziataVVlld:pubmed
pubmed-article:12747282pubmed:authorpubmed-author:MossettiGGlld:pubmed
pubmed-article:12747282pubmed:authorpubmed-author:RendinaDDlld:pubmed
pubmed-article:12747282pubmed:authorpubmed-author:NumisF GFGlld:pubmed
pubmed-article:12747282pubmed:issnTypePrintlld:pubmed
pubmed-article:12747282pubmed:volume21lld:pubmed
pubmed-article:12747282pubmed:ownerNLMlld:pubmed
pubmed-article:12747282pubmed:authorsCompleteYlld:pubmed
pubmed-article:12747282pubmed:pagination232-6lld:pubmed
pubmed-article:12747282pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:meshHeadingpubmed-meshheading:12747282...lld:pubmed
pubmed-article:12747282pubmed:articleTitleBiochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease.lld:pubmed
pubmed-article:12747282pubmed:affiliationDepartment of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy. nunziata@unina.itlld:pubmed
pubmed-article:12747282pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12747282pubmed:publicationTypeCase Reportslld:pubmed